Hepatic resection for disseminated germ cell carcinoma

R. J. Goulet, J. M. Hardacre, L. H. Einhorn, P. J. Loehrer, J. A. Jones, J. P. Donohue, J. A. Madura, J. L. Grosfeld

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Improvements in operative technique and perioperative management have expanded the application of hepatic resection for metastatic cancer. Although a policy of aggressive surgical resection of residual pulmonary and retroperitoneal disease following chemotherapy and normalization of serum tumor markers has been adopted for disseminated germ cell carcinoma, resection of residual hepatic disease in these cases has not been addressed. This report concerns a series of prospectively randomized patients who received systemic cisplatin-based chemotherapy for testis cancer during the past 13 years. Twenty-eight patients underwent resection of residual hepatic disease after serologic remission. Most (23 of 28 patients) of these procedures were preformed concomitantly with other cytoreductive procedures. There were no operative deaths, although 28% of the patients developed complications. The 2-year survival rate was 54%, with an average follow-up of 34 months. Patients were stratified into three groups based on the most aggressive histology noted in the resected specimen. Survival is predicted by this histologic classification system. Hepatic resection can be performed safely and is an important component in the treatment of disseminated testicular carcinoma.

Original languageEnglish (US)
Pages (from-to)290-294
Number of pages5
JournalAnnals of surgery
Volume212
Issue number3
DOIs
StatePublished - Jan 1 1990

    Fingerprint

ASJC Scopus subject areas

  • Surgery

Cite this

Goulet, R. J., Hardacre, J. M., Einhorn, L. H., Loehrer, P. J., Jones, J. A., Donohue, J. P., Madura, J. A., & Grosfeld, J. L. (1990). Hepatic resection for disseminated germ cell carcinoma. Annals of surgery, 212(3), 290-294. https://doi.org/10.1097/00000658-199009000-00007